Archive

Endocyte, Inc., and ITM Isotopen Technologien München AG (ITM) today announced a supply agreement under which ITM will supply to Endocyte the medical…

Read more

First Patient enrolled in Europe for the clinical study COMPETE at the University Hospital Marburg, Germany.

COMPETE to investigate a broad…

Read more

ITM’s subsidiary ITM Solucin lead 2-day-event focused on study update and efficient trial execution.

Meeting attended by over 60 investigators as…

Read more

With a 174 % growth, ITM Isotopen Technologien München AG is one of the 50 winners of the Deloitte Technology Fast 50 Award 2017

Read more

ITM Isotopen Technologien München AG (ITM), a specialized radiopharmaceutical company, today announced the enrollment of the first patient recruited…

Read more

ITM Isotopen Technologien München AG, a specialized radiopharmaceutical company, today announced that the European Medicines Agency (EMA) has granted…

Read more

ITM Isotopen Technologien München AG, a specialized radiopharmaceutical company, today announced that the Committee for Medicinal Products for Human…

Read more

ITM Isotopen Technologien München AG (ITM), a specialized radiopharmaceutical company, and Scil Proteins, the expert company in affinity ligands and…

Read more

Clinical development of Targeted Radionuclide Therapies to get major boost Investment will support growth initiatives of the company

Read more

The ITM Group announced today that its subsidiary ITG GmbH has successfully in-licensed DOTA-Zoledronate, a next generation theranostic agent for Bone…

Read more